Page 60 - Read Online

Page 238 Crisafulli et al. Cancer Drug Resist 2019;2:225-41 I http://dx.doi.org/10.20517/cdr.2018.008

Copyright
© The Author(s) 2019.

REFERENCES
1. Relli V, Trerotola M, Guerra E, Alberti S. Distinct lung cancer subtypes associate to distinct drivers of tumor progression. Oncotarget
2018;9:35528-40.
2. Ambrogi F, Biganzoli E, Querzoli P, Ferretti S, Boracchi P, et al. Molecular subtyping of breast cancer from traditional tumor marker
profiles using parallel clustering methods. Clin Cancer Res 2006;12:781-90.
3. Querzoli P, Pedriali M, Rinaldi R, Lombardi AR, Biganzoli E, et al. Axillary lymph node nanometastases are prognostic factors for
disease-free survival and metastatic relapse in breast cancer patients. Clin Cancer Res 2006;12:6696-701.
4. Querzoli P, Coradini D, Pedriali M, Boracchi P, Ambrogi F, et al. An immunohistochemically positive E-cadherin status is not always
predictive for a good prognosis in human breast cancer. Br J Cancer 2010;103:1835-9.
5. Biganzoli E, Coradini D, Ambrogi F, Garibaldi JM, Lisboa P, et al. p53 status identifies two subgroups of triple-negative breast cancers
with distinct biological features. Jpn J Clin Oncol 2011;41:172-9.
6. Tripaldi R, Stuppia L, Alberti S. Human height genes and cancer. BBA reviews cancer 2013;1836:27–41.
7. Zanna P, Trerotola M, Vacca G, Bonasera V, Palombo B, et al. Trop-1 is a novel cell growth stimulatory molecule that marks early
stages of tumor progression. Cancer 2007;110:452-64.
8. Guerra E, Trerotola M, Dell’ Arciprete R, Bonasera V, Palombo B, et al. A bi-cistronic CYCLIN D1-TROP2 mRNA chimera
demonstrates a novel oncogenic mechanism in human cancer. Cancer Res 2008;68:8113-21.
9. Guerra E, Trerotola M, Tripaldi R, Aloisi AL, Simeone P, et al. Trop-2 induces tumor growth through Akt and determines sensitivity to
Akt inhibitors. Clin Cancer Res 2016;22:4197-205.
10. Ambrogi F, Fornili M, Boracchi P, Trerotola M, Relli V, et al. Trop-2 is a determinant of breast cancer survival. PLoS One
2014;9:e96993.
11. Guerra E, Trerotola M, Aloisi AL, Tripaldi R, Vacca G, et al. The Trop-2 signalling network in cancer growth. Oncogene 2013;32:1594-
600.
12. Trerotola M, Cantanelli P, Guerra E, Tripaldi R, Aloisi AL, et al. Up-regulation of Trop-2 quantitatively stimulates human cancer
growth. Oncogene 2013;32:222-33.
13. De Vita VT, Lawrence TS, Rosenberg SA. De Vita, Hellman & Rosenberg’s Cancer: Principles & Practice of Oncology. Available from:
http://www.kubalibri.cz/files/176---DeVita,-Hellman,-and-Rosenberg-s-Cancer---Principles---Practice-of-Oncology.pdf. [Last accessed
on 9 Apr 2019]
14. Tomasetti C, Li L, Vogelstein B. Stem cell divisions, somatic mutations, cancer etiology, and cancer prevention. Science 2017;355:1330-4.
15. Trerotola M, Relli V, Simeone P, Alberti S. Epigenetic inheritance and the missing heritability. Hum Genomics 2015;9:17.
16. Simeone P, Alberti S. Epigenetic heredity of human height. Physiol Rep 2014;2:e12047.
17. Patel JN, Wiebe LA, Dunnenberger HM, McLeod HL. Value of supportive care pharmacogenomics in oncology practice. Oncologist
2018;23:956-64.
18. Cascorbi I, Bruhn O, Werk AN. Challenges in pharmacogenetics. Eur J Clin Pharmacol 2013;69 Suppl 1:17-23.
19. Garralda E, Paz K, Lopez-Casas PP, Jones S, Katz A, et al. Integrated next-generation sequencing and avatar mouse models for
personalized cancer treatment. Clin Cancer Res 2014;20:2476-84.
20. Gillis NK, Patel JN, Innocenti F. Clinical implementation of germ line cancer pharmacogenetic variants during the next-generation
sequencing era. Clin Pharmacol Ther 2014;95:269-80.
21. Adams DR, Eng CM. Next-generation sequencing to diagnose suspected genetic disorders. N Engl J Med 2018;379:1353-62.
22. Hynes SO, Pang B, James JA, Maxwell P, Salto-Tellez M. Tissue-based next generation sequencing: application in a universal
healthcare system. Br J Cancer 2017;116:553-60.
23. Klotz U. The role of pharmacogenetics in the metabolism of antiepileptic drugs: pharmacokinetic and therapeutic implications. Clin
Pharmacokinet 2007;46:271-9.
24. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999;286:487-91.
25. Pinto N, Cohn SL, Dolan ME. Using germline genomics to individualize pediatric cancer treatments. Clin Cancer Res 2012;18:2791-
800.
26. Crona D, Innocenti F. Can knowledge of germline markers of toxicity optimize dosing and efficacy of cancer therapy? Biomark Med
2012;6:349-62.
27. Stadler ZK, Schrader KA, Vijai J, Robson ME, Offit K. Cancer Genomics and Inherited Risk. Journal of Clinical Oncology
2014;32:687-98.
28. Shimelis H, LaDuca H, Hu C, Hart SN, Na J, et al. Triple-negative breast cancer risk genes identified by multigene hereditary cancer
panel testing. J Natl Cancer Inst 2018; Epub ahead of print, DOI: 10.1093/jnci/djy106.
29. Tai YC, Domchek S, Parmigiani G, Chen S. Breast cancer risk among male BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst
2007;99:1811-4.
30. Mavaddat N, Peock S, Frost D, Ellis S, Platte R, et al. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective
analysis of EMBRACE. J Natl Cancer Inst 2013;105:812-22.
31. Hahn SA, Greenhalf B, Ellis I, Sina-Frey M, Rieder H, et al. BRCA2 germline mutations in familial pancreatic carcinoma. JNCI Cancer